A Three-Ingredient Moisturizer Shows Early Promise for Rosacea's Redness, but Not Which Ingredient Matters Most

Rosacea moisturizers tend to get treated as an afterthought next to the prescription drugs that actually calm the redness. A new randomized controlled trial out of China argues that the formulation of the moisturizer itself changes outcomes, at least for the erythematotelangiectatic subtype, where flushing and visible blood vessels dominate the clinical picture.

The trial, published in Skin Research and Technology, enrolled 75 patients with erythematotelangiectatic rosacea. Everyone took oral minocycline 50 mg daily, a standard adjunct for rosacea's inflammatory component. The variable was the moisturizer: 39 patients used a formula built around Centella asiatica extract, ceramide NP, and panthenol, applied twice daily, while 36 patients served as controls. Researchers Xia Jiang, Haoyun Luo, Xiao He, Chenmin Hu, Kena Dan, Yongchao Dang, Tian Qian, Daojun Zhang, and Fei Hao tracked facial redness imaging, stratum corneum hydration, transepidermal water loss, and clinician erythema scores at baseline, day 7, day 14, and day 28.

Each of the three ingredients is doing a distinct job in the formula rather than working as a single blended active. Ceramide NP is a barrier lipid, one of the specific ceramide subtypes naturally present in the stratum corneum, and its role here is structural: replenishing the lipid matrix that keeps water from escaping through damaged rosacea-prone skin. Panthenol, the provitamin form of vitamin B5, is a humectant and known skin-conditioning agent that also has a documented soothing effect on irritated skin. Centella asiatica extract, long used in wound-healing contexts, is included for its reputed anti-inflammatory and vascular-supportive properties, which maps directly onto the telangiectatic component of this rosacea subtype.

The results favored the three-ingredient moisturizer across several measures. The authors reported that changes in a* value (a colorimetric measure of redness), facial red area, stratum corneum hydration, and quality-of-life scores from baseline to day 28 were, in their words, rapidly and significantly greater in the experimental group. Clinician's Erythema Assessment scores were significantly lower (better) in that group by day 28 as well. All adverse events across both arms were described as mild and self-limiting.

What the trial does not resolve is which of the three ingredients, or what concentration of each, is driving the benefit. The moisturizer was tested as a finished formulation, not as isolated components or a dose-response series, so the barrier-repair contribution of ceramide NP cannot be separated from the anti-inflammatory contribution attributed to Centella asiatica or the humectant effect of panthenol. The trial also ran for only 28 days in a single population of 75 Chinese patients on background minocycline, leaving open how the moisturizer performs as monotherapy, over longer stretches, or in other rosacea subtypes. The authors frame their formula as an adjunctive daily skincare option, a narrower claim than a standalone treatment, built on a barrier-repair rationale that rosacea's compromised stratum corneum has made a working premise across multiple published treatments, even as the specific credit assigned to each active ingredient remains, for now, untested in isolation.